Publicaciones en colaboración con investigadores/as de University of Padua (22)

2024

  1. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

    Seminars in Arthritis and Rheumatism, Vol. 66

2023

  1. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  2. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

2022

  1. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

    Human Genetics, Vol. 141, Núm. 1, pp. 147-173

  2. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ( € Registry')

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781

  2. Genetic mechanisms of critical illness in COVID-19

    Nature, Vol. 591, Núm. 7848, pp. 92-98

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts

    Lupus Science and Medicine, Vol. 8, Núm. 1

2020

  1. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

    Lupus, Vol. 29, Núm. 11, pp. 1353-1363

  2. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

  3. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

2019

  1. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159

  2. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304

  3. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 126, Núm. 5, pp. 656-661

  4. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis

    Thrombosis Research, Vol. 175, pp. 32-36

2016

  1. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480

2013

  1. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients

    ARTHRITIS AND RHEUMATISM

2011

  1. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS)

    ARTHRITIS AND RHEUMATISM